SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eyetech Pharmaceutical (EYET)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: RAYS5/25/2005 9:24:56 AM
  Read Replies (1) of 6
 
It's too bad wall street does not understand the pathophysiology of wet AMD. No drug can reverse the retinal damage of AMD. VEGF inhibitors may slow down or at best stop further damage. Vision improvement suggested in the Genentech trial is probably due to reduction in macular edema and should therefore be limited. Once the edema is reduced then no further improvement should be expected. Critical review of Genentech data and study design is needed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News